SEM Healthcare Services · Post-acute care · Take-private · Delisted · Thesis updated July 2, 2026

The public SEM story ended in cash

Select Medical completed its take-private deal, and public holders were set to receive $16.50 per share in cash.
The company is now a private post-acute care operator, not a normal public stock idea.
Before the close, the best business was Rehabilitation Hospital, where Q1 Adjusted EBITDA rose 15.1% and margin held at 23.0%.
Critical Illness was weaker, with Q1 margin down to 11.5% from 13.6% after lower Medicare Advantage conversions.
Outpatient Rehabilitation also struggled, and management was closing weak markets and changing schedules to protect margins.

01 Running thesis

Cash-out, not comeback

The main SEM stock thesis has played out. The company agreed to be acquired for $16.50 per share in cash, stockholders approved the deal, and the merger closed around the start of July 2026. That means the normal public-stock question is no longer, can this business compound value for outside holders. The question is now mostly about the completed cash-out and any leftover corporate action details for former holders.

Before the close, the bull case was simple: the deal would finish on time. That case got stronger when the Hart-Scott-Rodino antitrust waiting period expired on April 27, then it was confirmed when the deal closed. The public market upside became the spread between the trading price and the cash price.

The bear case was deal failure. If the merger had broken, investors would have been left with a slower and messier operating story. Critical Illness margins were under pressure from payor mix, and Outpatient Rehabilitation was still being repaired. The strong Rehabilitation Hospital segment helped, but it did not erase those problems.

Jul 2026▲The take-private transaction closed, ending the public SEM equity story. Former holders were set to receive $16.50 per share in cash.

Jun 2026▲Stockholders approved the acquisition by the consortium led by Robert A. Ortenzio, Martin F. Jackson, and WCAS. This removed the biggest remaining closing condition.

May 2026▲The Hart-Scott-Rodino waiting period expired on April 27, which lowered deal risk. The earnings call also showed that Critical Illness weakness was tied to lower Medicare Advantage conversions.

Apr 2026→The Q1 2026 10-Q confirmed the $16.50 per share merger agreement. It also showed weaker margins in Critical Illness and Outpatient Rehabilitation, while Rehabilitation Hospital stayed strong.

Feb 2026▼The Q4 2025 call shifted more concern toward Outpatient Rehabilitation after a sharp margin drop. Management described about $11 million of specific cost headwinds in that segment.

Feb 2026▲The 2025 10-K introduced a take-private proposal from Executive Chairman Robert A. Ortenzio at $16.00 to $16.20 per share. That made the stock more event-driven than operations-driven.

Oct 2025▼Management said the Q3 Critical Illness margin lift included a one-time $12 million to $15 million EBITDA benefit from a delayed Medicare rule. That weakened the idea of a true operating recovery.

Jul 2025→The Q2 2025 10-Q showed the split in the business. Rehabilitation Hospital kept growing, but Critical Illness margins compressed because of Medicare reimbursement changes.

02 Business model

Paid by insurers and Medicare

Select Medical operates care sites for people after a major illness, injury, or hospital stay. Its customers are patients, but the money usually comes from Medicare, Medicare Advantage plans, commercial insurers, and other private payors.

The model depends on referrals. General hospitals send patients to Select Medical when they need long-term acute care, inpatient rehab, or outpatient therapy. Scale helps because a large network can build trusted hospital relationships across many local markets.

The weak spot is reimbursement. If Medicare rules change, if Medicare Advantage plans approve fewer patients, or if insurers pay less per visit, revenue can fall while labor and facility costs stay high. That is why small changes in patient mix can move margins.

03 Product portfolio

Recovery care across three settings

Cash cow

Critical Illness Recovery Hospitals

These are long-term acute care hospitals for very sick patients who still need hospital-level treatment. Select Medical had 104 locations at year-end 2025.

Growth engine

Rehabilitation Hospitals

These inpatient rehab hospitals treat patients who need intense physical recovery after events like strokes, injuries, or major illness. This was the standout segment in Q1 2026.

Steady

Outpatient Rehabilitation Clinics

These clinics provide physical, occupational, and speech therapy after patients leave the hospital. Select Medical had 1,917 clinics at year-end 2025, but margins were under pressure.

Option

Hospital referral network

The company’s local hospital relationships help fill beds and clinics. This network matters because many patients come through referrals after an acute hospital stay.

04 Business segments

Q1 mix, one strong leg

Critical Illness Recovery Hospital48%declining

Rehabilitation Hospital27%growing fast

Outpatient Rehabilitation25%declining

Segment mix is based on Q1 2026 revenue implied by reported Adjusted EBITDA and margins in the latest 10-Q. Rehabilitation Hospital was the healthiest segment, while Critical Illness and Outpatient Rehabilitation had margin pressure.

05 Risk factors

What could still matter

Post-close payment issue

Medium impact · Low odds

The public equity deal has closed, so the main risk for former holders is administrative. Some investors may still need to process cash election, broker timing, or record-holder steps. This is not the same as normal market risk, but it matters if cash has not appeared in an account.

We watchBroker notices and payment timing for the $16.50 per share merger consideration.

Less public reporting

High impact · High odds

Select Medical is now private, so investors should expect less regular public information. That makes the business harder to track from the outside. Future performance will matter more to private owners, lenders, employees, and partners than to public common stockholders.

We watchNYSE delisting notices and any later SEC filings about termination of public reporting.

Medicare Advantage conversion weakness

High impact · Medium odds

In Q1 2026, management said lower Medicare Advantage conversion rates hurt Critical Illness performance by about $13 million to $14 million year over year. That is a real operating problem because fewer approved patients can reduce volume and margin. If it continues, the largest care setting has less earnings power.

We watchCritical Illness patient conversions, admissions, and Adjusted EBITDA margin.

Outpatient turnaround stalls

Medium impact · Medium odds

Outpatient Rehabilitation Adjusted EBITDA fell in Q1 2026, and margin dropped to 6.8% from 7.9%. Management was using schedule changes and market exits, including closing 4 Oregon clinics at about $1 million of cost. If those fixes do not work, the clinic base stays lower-margin.

We watchOutpatient Rehabilitation margin and the number of clinics closed or exited.

Medicare rule pressure

Medium impact · Medium odds

Critical Illness hospitals depend on Medicare rules for part of their economics. Prior filings flagged pressure from high-cost outlier payment rules, which can reduce payments for costly cases. Even under private ownership, rule changes can still hit cash flow.

We watchCMS updates on LTCH payment rates and high-cost outlier thresholds.

06 Quick answers

In one breath

Is SEM still publicly traded?

No. Select Medical completed its take-private transaction around the start of July 2026, and its common stock was delisted from the NYSE. Former public holders were set to receive $16.50 per share in cash.

What does Select Medical do?

Select Medical runs post-acute care facilities. These include critical illness recovery hospitals, inpatient rehabilitation hospitals, and outpatient rehab clinics.

What was the main investment thesis before the deal closed?

The main thesis was whether the take-private deal would close at $16.50 per share. Operating fundamentals mattered, but they became secondary once the merger agreement was signed.

Which part of the business was strongest?

Rehabilitation Hospital was the strongest segment in Q1 2026. Revenue rose 14.5%, Adjusted EBITDA rose 15.1%, and margin held at 23.0%.